Arkana Therapeutics, a biotech startup focused on developing innovative medicines for metabolic diseases, has closed a $750K pre-seed funding round. The company's unique drug discovery approach leverages the natural biology of animals with extreme metabolic adaptations, aiming to uncover therapies that can prevent and reverse these conditions in humans.
By following this evolutionarily-honed blueprint found in nature, Arkana is developing first-in-class therapies. These treatments are designed to transform human metabolic health by offering new ways to prevent and reverse metabolic diseases.
